Showing 4001-4010 of 5771 results for "".
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Nicox Does Not Meet Primary or Secondary Endpoints in Phase 2b Mississippi Blepharitis Trialhttps://modernod.com/news/nicox-does-not-meet-primary-or-secondary-endpoint-in-phase-2b-mississippi-blepharitis-trial/2480300/Nicox SA announced the results from its Mississippi phase 2b clinical trial evaluating once-daily dosed NCX 4251, fluticasone propionate ophthalmic suspension 0.1%, against placebo in patients with acute exacerbations o
- RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditionshttps://modernod.com/news/rd-fund-launches-opus-genetics-with-19m-seed-funding-to-advance-gene-therapy-treatments-for-blinding-conditions/2480298/The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, announced the launch of
- FYidoctors Makes Expansion into US Markethttps://modernod.com/news/fyidoctors-makes-expansion-into-us-market/2480296/Canadian eye care provider FYidoctors announced that it has expanded its geographic operations into the US marketplace with the addition of six leading eye care clinics throughout the state of California. The foray marks a major company milestone as the first time FYidoctors has ad
- Clearside Biomedical Completes Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX in Wet AMD Patientshttps://modernod.com/news/clearside-biomedical-completes-dosing-in-cohort-2-of-phase-12a-clinical-trial-of-cls-ax-in-wet-amd-patients/2480292/Clearside Biomedical announced completion of dosing in Cohort 2 of OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) in patients with wet age-related macular degeneration (AMD). OASIS is a U.S.-based, multicenter
- Novartis Acquires Arctos Medical, Expanding Optogenetics Portfoliohttps://modernod.com/news/novartis-acquires-arctos-medical-expanding-optogenetics-portfolio-to-bring-gene-therapies-to-patients-with-severe-vision-loss/2480291/Novartis announced that it has acquired Arctos Medical, adding a preclinical optogenetics-based AAV gene therapy program and Arctos’ proprietary technology to its ophthalmology portfolio. Financial terms of the deal were not disclosed. “Optogenetics is emergi
- TissueTech Hosts Inaugural Leadership Summit to Discuss Best Practices on Regenerative Medicinehttps://modernod.com/news/tissuetech-hosts-inaugural-leadership-summit-to-discuss-best-practices-on-regenerative-medicine/2480288/TissueTech announced that the company had completed its first physician leadership summit, Beyond the Horizon 2021,
- Results Published From 2-year Multicenter Study Illustrate Efficacy and Safety of Preserflo MicroShunthttps://modernod.com/news/results-published-from-2-year-multicenter-study-illustrate-efficacy-and-safety-of-preserflo-microshunt/2480287/Santen EMEA has announced the results from a 2-year multicenter study of the Preserflo MicroShunt in patients with primary open-angle glaucoma (POAG). The study showed that mean IOP was significantly reduced from 21.7±3.4 mmHg at baseline to 14.1±3.2 mmHg at year 2 (&
- First Ophthalmology Biosimilar Approved in the United Stateshttps://modernod.com/news/fda-approves-samsung-bioepis-and-biogens-byooviz-lucentis-biosimilar-ranibizumab-nuna/2480286/Samsung Bioepis and Biogen announced that the FDA has approved Byooviz (ranibizumab-nuna), a biosimilar referencing Lucentis (ranibizumab)i, for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (R
- Sight Sciences Files Lawsuit Against Ivantis for Patent Infringementhttps://modernod.com/news/sight-sciences-files-lawsuit-against-ivantis-for-patent-infringement/2480283/Sight Sciences announced that it has filed a lawsuit in the United States District Court in Delaware against Ivantis for infringement of U.S. Patents that describe and claim devices and methods for reducing intraocular pressure in the eye. The patents are Numbers 8,287,48